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Objective: 
Novel imaging techniques for prostate cancer (PCa) are required to improve staging and real-time 
assessment of therapeutic response. We performed preclinical evaluation of newly-developed, 
biocompatible magnetic nanoparticles (MNPs) conjugated with J591, an antibody specific for 
prostate specific membrane antigen (PSMA), to enhance magnetic resonance imaging (MRI) of PCa. 
PSMA is expressed on ~90% of PCa, including those that are castrate-resistant, rendering it as a 
rational target for PCa imaging.  
Methods: 
The specificity of J591 for PSMA was confirmed by flow cytometric analysis of several PCa cell 
lines of known PSMA status. MNPs were prepared, engineered to the appropriate size, labeled 
with DiR fluorophore, and their toxicity to a panel of PC cells was assessed by in vitro Alamar Blue 
assay. Immunohistochemistry, fluorescence microscopy and Prussian Blue staining (iron uptake) 
were used to evaluate PSMA specificity of J591-MNP conjugates. In vivo MRI studies (16.4T MRI 
system) were performed using live immunodeficient mice bearing orthotopic LNCaP xenografts 
and injected intravenously with J591-MNPs or MNPs alone. 
Results: 
MNPs were non-toxic to PCa cells. J591-MNP conjugates showed no compromise in specificity of 
binding to PSMA+ cells and showed enhanced iron uptake compared with MNPs alone. In vivo, 
tumour targeting (significant MR image contrast) was evident in mice injected with J591-MNPs, 
but not MNPs alone. Resected tumours from targeted mice had an accumulation of MNPs, not seen 
in normal control prostate.  
Conclusion: 
Application of PSMA-targeting MNPs into conventional MRI has potential to enhance PCa 
detection and localization in real-time, improving patient management.   
 
